AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33879769
Drug: SEP-363856 10
RxNorm normalized name: atropine sulfate / benzoic acid / hyoscyamine sulfate / methenamine / methylene blue / phenyl salicylate Oral Tablet [Uri-Sep]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEP-363856 10 mg
Trial: 36344851
Drug: R0 resection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R0 resection and lenvatinib-transarterial chemoembolization (lenvatinib-TACE) sequential therapy
Trial: 36344851
Drug: Other non-curative-intent
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other non-curative-intent subsequent treatment
Trial: 36344851
Drug: R0 resection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R0 resection and lenvatinib-TACE sequential therapy
Trial: 36344851
Drug: Non-curative-intent subsequent
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-curative-intent subsequent treatment
Trial: 34981493
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil ointment (85% olive oil), applied twice a day for 4 days
Trial: 34981493
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment (85% liquid paraffin, similar in color and odor to olive oil ointment), applied twice a day for 4 days
Trial: 32244028
Drug: Dengzhan Shengmai
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengzhan Shengmai (DZSM) capsules
Trial: 33508236
Drug: Superficial nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Superficial nerve block (SNB) with 1.8 mL of 2% lidocaine and 1:100,000 epinephrine
Trial: 33508236
Drug: Conventional technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional technique (CT) with 1.8 mL of 2% lidocaine and 1:100,000 epinephrine
Trial: 36441736
Drug: Intranasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal insulin (INI)
Trial: 32969563
Drug: Cabozantinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (40 mg) plus docetaxel (75 mg/m2 every 3 weeks) and prednisone (10 mg daily)
Trial: 32969563
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2 every 3 weeks) and prednisone (10 mg daily) alone
Trial: 35905636
Drug: Daily massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily massage therapy administered by the mother from 34 weeks' to 40 weeks' corrected age (CA)
Trial: 34293233
Drug: Esketamine plus
RxNorm normalized name: esketamine
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine plus oral antidepressant
Trial: 34293233
Drug: Antidepressant/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant/placebo
Trial: 34508886
Drug: 14-day treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14-day treatment
Trial: 32388584
Drug: Enteric-coated NaHCO3
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated NaHCO3 (0.3 g∙kg‐1 body mass)
Trial: 32388584
Drug: Gelatin NaHCO3
RxNorm normalized name: sodium bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gelatin NaHCO3 (0.3 g∙kg‐1 body mass)
Trial: 32394874
Drug: Miltefosine monotherapy
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Miltefosine monotherapy
Trial: 36196796
Drug: Complex 1
RxNorm normalized name: B-COMPLEX 100 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex 1 ([Fe(L)][Fe(bpb)(CN)2]·CH3OH·0.5H2O)
Trial: 36196796
Drug: Complex 2
RxNorm normalized name: hesperidin complex 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex 2 ([Fe(L)][Co(bpb)(CN)2]·CH3OH)
Trial: 36196796
Drug: Complex 3
RxNorm normalized name: chlorophyllin copper complex 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex 3 ([(Fe (L))2(4,4'‐bipy)](BPh4)2)
Trial: 36196796
Drug: Complex 4
RxNorm normalized name: polysaccharide iron complex 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex 4 ([Fe(L)(py)](BPh4))
Trial: 36196796
Drug: Complex 5
RxNorm normalized name: B-Complex 50
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Complex 5 ([Fe(L)(dmap)](BPh4))
Trial: 32954451
Drug: Cypermethrin (CYP)
RxNorm normalized name: cypermethrin
DrugBank: Cypermethrin (DB13721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cypermethrin (CYP) treatment at 10 μg mL‐1
Trial: 32954451
Drug: Cypermethrin (CYP)
RxNorm normalized name: cypermethrin
DrugBank: Cypermethrin (DB13721)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cypermethrin (CYP) treatment
Trial: 33349011
Drug: Mg+H2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg+H2
Trial: 33349011
Drug: Mg and
RxNorm normalized name: Vraylar 1.5mg and 3mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg and Mg+H2
Trial: 32255542
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg esaxerenone
Trial: 32255542
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg esaxerenone
Trial: 35085663
Drug: Allergen immunotherapy
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy (subcutaneous and sublingual) continued for a minimum of 3 years
Trial: 35085663
Drug: Grass pollen
RxNorm normalized name: grass pollen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grass pollen immunotherapy for seasonal rhinitis
Trial: 35085663
Drug: Mite sublingual
RxNorm normalized name: mite,D.farinae-D.pteronyssinus 12 standardized quality-house dust mite SUBLINGUAL TABLET, SUBLINGUAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mite sublingual immunotherapy
Trial: 37275956
Drug: 1% hydrocortisone
RxNorm normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1% hydrocortisone ointment
Trial: 33181557
Drug: Ibuprofen 10
RxNorm normalized name: ibuprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 10 mg·kg‐1
Trial: 33181557
Drug: Propacetamol 30
RxNorm normalized name: Propanetriol
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol 30 mg·kg‐1
Trial: 33181557
Drug: Ibuprofen 10
RxNorm normalized name: ibuprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 10 mg·kg‐1 + Propacetamol 30 mg·kg‐1
Trial: 32787932
Drug: Group Interpersonal
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Interpersonal Therapy (IPT) adapted for adolescents; delivered in secondary schools by school nurses and lay community members; includes parental engagement components and locally acceptable terms for mental illness.
Trial: 35546458
Drug: Coconut cream
RxNorm normalized name: ALCOHOL 620 mg in 1 mL TOPICAL LIQUID [TOPCARE COCONUT CREAM]
DrugBank: Coconut (DB10523)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coconut cream 50%
Trial: 34247834
Drug: Real world
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real world data as a comparator for single-arm treatment trials
Trial: 34806331
Drug: Progesterone soft
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone soft capsule under fasting conditions
Trial: 34806331
Drug: Progesterone soft
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone soft capsule under fed conditions (high-fat meal, 890 kcal)
Trial: 34626515
Drug: Bortezomib (Btz)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib (Btz) in combination with melphalan and prednisolone (MPB)
Trial: 33066974
Drug: SSRI exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI exposure (fluoxetine, sertraline, escitalopram/citalopram)
Trial: 33066974
Drug: Fluoxetine exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine exposure
Trial: 34043621
Drug: Mosquito Exposure
RxNorm normalized name: mosquito allergenic extract
DrugBank: Aedes taeniorhynchus (DB10691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mosquito Exposure Index (MEI) measured by ELISA for anti-Aedes saliva antibodies
Trial: 32182219
Drug: VRC01 infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VRC01 infusion
Trial: 35193729
Drug: Cariprazine 6
RxNorm normalized name: cariprazine 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 6 mg/d
Trial: 32297352
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus 2-weekly home end-of-life and palliative care coaching by experienced community nurses
Trial: 39117415
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg daily aspirin
Trial: 39117415
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg daily aspirin
Trial: 36373571
Drug: man therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: man therapy (MT)
Trial: 34007070
Drug: CoVLP (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoVLP (3.75 μg, 7.5 μg, and 15 μg)
Trial: 32568399
Drug: Sertraline hydrochloride
RxNorm normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline hydrochloride (n = 176)
Trial: 32568399
Drug: Extended-release venlafaxine
RxNorm normalized name: venlafaxine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release venlafaxine hydrochloride (n = 180)
Trial: 33386332
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 9vHPV vaccine (0, 6 regimen)
Trial: 33386332
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 9vHPV vaccine (0, 12 regimen)
Trial: 33386332
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 9vHPV vaccine (0, 2, 6 regimen)
Trial: 34189463
Drug: Bevacizumab therapy
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab therapy
Trial: 33636356
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Solution (NSS)
Trial: 33636356
Drug: Savlon Solution
RxNorm normalized name: Savlon Dry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Savlon Solution
Trial: 35575284
Drug: Hochuekkito administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hochuekkito administration
Trial: 35575284
Drug: Control (non-hochuekkito
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-hochuekkito administration)
Trial: 33724513
Drug: Experimental arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental arm (specific treatment not detailed)
Trial: 33253833
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixekizumab (IXE) 80 mg every 2 weeks
Trial: 33253833
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ixekizumab (IXE) 80 mg every 4 weeks
Trial: 36307361
Drug: Botulinum Toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum Toxin A (BTA) - 50 units injected twice, 3 months apart
Trial: 34169543
Drug: AUC estimated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AUC estimated from trough-only data using derived volume of distribution (Vd) equation: Vd (L) = 0.29(age) + 0.33(total BW in kg) + 11
Trial: 34706949
Drug: Average treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average treatment effect of CRT response
Trial: 32628039
Drug: Capillary microsampling
RxNorm normalized name: Artemisia capillaris leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capillary microsampling of 15 μl whole blood from fingersticks or heelsticks in a respiratory syncytial virus drug study
Trial: 34861685
Drug: Granulox therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulox therapy twice weekly
Trial: 34861685
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (once-weekly podiatric medical clinic visits)
Trial: 32574138
Drug: Caregiver concerns
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiver concerns for MMR vaccine
Trial: 34768692
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no biofeedback therapy)
Trial: 32400227
Drug: No past
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No past month drug use
Trial: 35749253
Drug: Etelcalcetide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide plus oral calcium (E+Ca group)
Trial: 34342134
Drug: Rectal spacer
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal spacer
Trial: 34342134
Drug: No rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rectal spacer
Trial: 36229113
Drug: Behavioral Experiments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Experiments for Intolerance of Uncertainty (12 weekly 1-hour sessions)
Trial: 37757502
Drug: Specialized oral
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized oral nutritional supplement (S-ONS)
Trial: 35421949
Drug: Focused Acceptance
RxNorm normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focused Acceptance and Commitment Therapy (FACT-CP)
Trial: 35233271
Drug: FES-cycling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FES-cycling and standard treatment
Trial: 35233271
Drug: Sham stimulus
RxNorm normalized name: Limulus polyphemus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham stimulus FES-cycling and standard treatment
Trial: 33099752
Drug: Ropeginterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropeginterferon alfa‐2b 350 μg (group 1)
Trial: 33099752
Drug: Ropeginterferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropeginterferon alfa‐2b 450 μg (group 2)
Trial: 33099752
Drug: PEG‐IFN alfa‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN alfa‐2a 180 μg (group 3)
Trial: 34004418
Drug: Sulforaphane (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulforaphane (30 mg/d)
Trial: 33963594
Drug: 8-week multimodal
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week multimodal intervention (ATENTO) prior to adjuvant chemotherapy (ATENTO-B)
Trial: 33963594
Drug: 8-week multimodal
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week multimodal intervention (ATENTO) throughout adjuvant chemotherapy (ATENTO-T)
Trial: 34763599
Drug: Heat-stable carbetocin
RxNorm normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-stable carbetocin 100 μg IM
Trial: 34933316
Drug: Povidone‐iodine in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone‐iodine in aqueous solution
Trial: 32220595
Drug: Dexamethasone 0.1
RxNorm normalized name: dexamethasone 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.1 mg/mL solution in Mucolox (arm A)
Trial: 32220595
Drug: Dexamethasone 0.1
RxNorm normalized name: dexamethasone 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.1 mg/mL solution alone (arm B)
Trial: 36301019
Drug: Fentanyl (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (25 µg) with 0.5% hyperbaric bupivacaine (3 mL)
Trial: 36301019
Drug: Nalbuphine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (0.8 mg) with 0.5% hyperbaric bupivacaine (3 mL)
Trial: 35707866
Drug: Oral tomato
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tomato extract supplement containing lycopene 30 mg
Trial: 34444764
Drug: Mangosteen and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mangosteen and propolis extracts (MAEC) - daily intake of a single capsule containing 194 mg for eight weeks
Trial: 35960141
Drug: Acupuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture with additional manual-movement or mind–body CIM therapies (group B)
Trial: 32412314
Drug: 5% minoxidil
RxNorm normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5% minoxidil twice daily for 24 weeks
Trial: 32412314
Drug: Microneedle therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedle therapy every 3 weeks for eight treatments
Trial: 32412314
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of microneedling and 5% minoxidil for a total of 24 weeks
Trial: 32186395
Drug: PPI +
RxNorm normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI + mucolytics
Trial: 35332542
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT)-based group counseling
Trial: 34025683
Drug: Mastiha supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mastiha supplementation (2.1 g/day) for 6 months
Trial: 33471961
Drug: Lower milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower milk consumption (<220 g/day)
Trial: 32627052
Drug: High flavanol
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flavanol (HF) chocolate bar (1060 mg)
Trial: 32627052
Drug: Moderate flavanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate flavanol (MF) chocolate bar (746 mg)
Trial: 32627052
Drug: Low flavanol
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low flavanol (LF) chocolate bar (406 mg)
Trial: 32627052
Drug: Control (CON)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control (CON) chocolate bar (88 mg)
Trial: 38583091
Drug: High-dose trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose trivalent inactivated influenza vaccine
Trial: 32541370
Drug: Citicoline eyedrops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline eyedrops 3 times daily for 3 years
Trial: 32541370
Drug: Placebo 3
RxNorm normalized name: placebo 330 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 3 times daily for 3 years
Trial: 32367180
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2, four weekly infusions)
Trial: 34196632
Drug: Multimedia Psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimedia Psychotherapy (with psycho-pharmacological therapy)
Trial: 34196632
Drug: Psycho-pharmacological therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psycho-pharmacological therapy and Multimedia Psychotherapy
Trial: 35754298
Drug: Pertuzumab, trastuzumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab, trastuzumab, and physician's choice chemotherapy (PTC)
Trial: 35754298
Drug: Trastuzumab and
RxNorm normalized name: pertuzumab and trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab and physician's choice chemotherapy (TC)
Trial: 32721104
Drug: Nicotinamide (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide (1.5 g/day for 6 weeks, then 3.0 g/day for 6 weeks)
Trial: 34802729
Drug: Bupivacaine liposome
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine liposome suspension block, oral placebo (BUP)
Trial: 34802729
Drug: Lidocaine block,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine block, oral placebo (LID)
Trial: 34802729
Drug: Lidocaine block,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine block, oral meloxicam (1 mg/kg of body weight; LID + MEL)
Trial: 34802729
Drug: Saline block,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline block, oral placebo (CON)
Trial: 34802729
Drug: Saline block,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline block, oral placebo, sham dehorn (SHAM)